Last reviewed · How we verify
Additional doses of Rituximab
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Rheumatoid arthritis, Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Additional doses of Rituximab |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. By binding to CD20, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune responses and is effective in conditions driven by pathogenic B cells.
Approved indications
- Rheumatoid arthritis
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Nausea
Key clinical trials
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) (PHASE2)
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain (PHASE2)
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (PHASE2)
- Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (PHASE1, PHASE2)
- Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additional doses of Rituximab CI brief — competitive landscape report
- Additional doses of Rituximab updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI